Survival
98%
survival to date across treated cases
BIO-PLY™ · A multimodal biologic
Succeeds where standard of care fails.
Peptide-rich platelet derivative for joint sepsis, sterile inflammation, and tissue repair.
AntimicrobialAnti-inflammatoryChondroprotective
The problem
Septic arthritis is devastating to horses.
When a joint, tendon sheath, or bursa becomes infected, the current standard of care often can't keep up, and the damage compounds fast.
Septic arthritis
Infection that won't clear
Bacteria hide in antibiotic-resistant biofilms, so standard antibiotics can't reach or clear the infection.
Cartilage destroyed
Runaway inflammation eats away at cartilage and soft tissue, often irreversibly.
Careers and lives lost
Many affected horses never return to performance, and some do not survive.
With BIO-PLY™
Treat the infection, not just the symptoms.
Goes after the infection
Directly antibacterial, active even against the biofilms that shield bacteria from antibiotics.
Calms joint inflammation
Resolves runaway inflammation without shutting down a productive immune response.
Protects cartilage
Helps preserve cartilage and soft tissue from the irreversible damage of joint sepsis.
The product
What is BIO-PLY™?
A peptide-rich platelet derivative, manufactured under cGMP.
BIO-PLY™ is a peptide-rich cocktail derived from platelets. The exact peptides are proprietary; using our biomanufacturing process we capture and concentrate a group of peptides with specific structure and function, curated for maximal activity. Developed by a prominent equine research laboratory and spun out with the inventors at the helm, BIO-PLY™ has been extensively tested in vitro and retains its activity in vivo.
We manufacture BIO-PLY™ under cGMP using cutting-edge bioprocessing techniques from platelets donated by a closed herd of horses screened and verified free of transmissible infectious diseases. Each lot undergoes strict release criteria and is tested for activity before release.
- Tested in vitro
- Active in vivo
- cGMP closed herd
- Per-lot activity testing
Veterinarian voices
Heard from the field.
Patient story
From career-ending injury to the winner's circle.
Far Better, a 7-year-old pacing gelding given a prognosis of "won't race again."
Before BIO-PLY™
Standard of care fails
- Severe septic joint
- Multiple surgeries
- Not responding to antibiotics
- Two years out of racing
- Prognosis: "won't race again"
After BIO-PLY™
Back to racing
- Rapid reduction in swelling
- Restored joint flexibility
- Returned to racing in month 4
- Back in the winner's circle in month 5
Built for the septic joint
Purpose-built to treat joint sepsis.
BIO-PLY™ was developed specifically for infected joints, where the standard of care struggles most.
Directly antibacterial
Attacks the infection
Active against the biofilms that shield bacteria in septic joints, reaching infection that standard antibiotics can't.
A short dosing course
Simple in-clinic dosing
Delivered as intra-articular injections into the affected joint over a short course of treatment, with improvement often seen quickly.
Calms & protects
Protects the joint
Reduces the synovial inflammation that drives cartilage damage, helping preserve the joint as it recovers.
The engine behind BIO-PLY™
Designed for consistent clinical performance.
Every dose is held to the same standard, from the source herd to the vial.
Step 01
Proprietary donor herd
- FDA-compliant closed herd in Blacksburg, Virginia.
- Screened and verified free of transmissible infectious diseases.
- Bi-weekly blood draws are pooled for maximum biological activity and consistency.
Step 02
Bio-processing & manufacturing
- cGMP, sterile manufacturing at each stage of production.
- Platelets are isolated, lysed, and concentrated to yield high-potency bioactive peptides.
- Shelf-stable BIO-PLY™ ready for immediate clinical deployment.
In-vivo study results
Encouraging outcomes vs. standard of care.
In our multi-site in-vivo study, BIO-PLY™ outperformed the current standard of care for septic synovitis, without a single adverse event reported to date.
Return to athletic function
85%
returned to athletic function
Results are still being collected and are subject to change. Standard-of-care figures are historical, drawn from a meta-analysis of published literature.
Development status
Where BIO-PLY™ is today
- Discovery
- Preclinical
- In Trials
- FDA Journey
- Available
Available · FDA journey underway
See the full product pipelineAvailable now
Ready to put BIO-PLY™ to work?
Request access below — it's the official channel for veterinary practices to purchase BIO-PLY™.
Contact us